vs
Primis Financial Corp.（FRST）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Primis Financial Corp.的季度营收约是REGENXBIO Inc.的1.5倍（$45.6M vs $30.3M），Primis Financial Corp.净利率更高（16.0% vs -221.3%，领先237.4%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 13.0%）
Primis金融集团是一家总部位于美国的金融控股公司，运营多家全服务银行子公司，面向个人及企业客户提供存款、贷款、按揭、财富管理等多元化金融服务，核心业务覆盖美国中大西洋沿岸区域。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FRST vs RGNX — 直观对比
营收规模更大
FRST
是对方的1.5倍
$30.3M
净利率更高
FRST
高出237.4%
-221.3%
两年增速更快
RGNX
近两年复合增速
13.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.6M | $30.3M |
| 净利润 | $7.3M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 16.0% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | 200.0% | -31.2% |
| 每股收益（稀释后） | $0.30 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FRSTRGNX
| Q1 26 | $45.6M | — | ||
| Q4 25 | $80.9M | $30.3M | ||
| Q3 25 | $41.0M | $29.7M | ||
| Q2 25 | $43.2M | $21.4M | ||
| Q1 25 | $58.7M | $89.0M | ||
| Q4 24 | $38.8M | $21.2M | ||
| Q3 24 | $37.3M | $24.2M | ||
| Q2 24 | $35.7M | $22.3M |
净利润FRSTRGNX
| Q1 26 | $7.3M | — | ||
| Q4 25 | $29.5M | $-67.1M | ||
| Q3 25 | $6.8M | $-61.9M | ||
| Q2 25 | $2.4M | $-70.9M | ||
| Q1 25 | $22.6M | $6.1M | ||
| Q4 24 | $-26.2M | $-51.2M | ||
| Q3 24 | $1.2M | $-59.6M | ||
| Q2 24 | $3.4M | $-53.0M |
毛利率FRSTRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率FRSTRGNX
| Q1 26 | — | — | ||
| Q4 25 | 44.8% | -190.0% | ||
| Q3 25 | 21.3% | -176.3% | ||
| Q2 25 | 6.9% | -296.3% | ||
| Q1 25 | 41.9% | 13.6% | ||
| Q4 24 | -123.0% | -242.1% | ||
| Q3 24 | -3.1% | -256.6% | ||
| Q2 24 | 7.8% | -251.3% |
净利率FRSTRGNX
| Q1 26 | 16.0% | — | ||
| Q4 25 | 36.5% | -221.3% | ||
| Q3 25 | 16.7% | -208.3% | ||
| Q2 25 | 5.6% | -331.8% | ||
| Q1 25 | 38.6% | 6.8% | ||
| Q4 24 | -100.3% | -241.3% | ||
| Q3 24 | 3.3% | -246.3% | ||
| Q2 24 | 9.6% | -237.7% |
每股收益（稀释后）FRSTRGNX
| Q1 26 | $0.30 | — | ||
| Q4 25 | $1.19 | $-1.30 | ||
| Q3 25 | $0.28 | $-1.20 | ||
| Q2 25 | $0.10 | $-1.38 | ||
| Q1 25 | $0.92 | $0.12 | ||
| Q4 24 | $-0.95 | $-0.99 | ||
| Q3 24 | $0.05 | $-1.17 | ||
| Q2 24 | $0.14 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $159.9M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $427.2M | $102.7M |
| 总资产 | $4.3B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FRSTRGNX
| Q1 26 | $159.9M | — | ||
| Q4 25 | $143.6M | $230.1M | ||
| Q3 25 | $63.9M | $274.2M | ||
| Q2 25 | $94.1M | $323.3M | ||
| Q1 25 | $57.0M | $267.9M | ||
| Q4 24 | $64.5M | $234.7M | ||
| Q3 24 | $77.3M | $255.5M | ||
| Q2 24 | $66.6M | $290.4M |
股东权益FRSTRGNX
| Q1 26 | $427.2M | — | ||
| Q4 25 | $422.9M | $102.7M | ||
| Q3 25 | $382.2M | $161.5M | ||
| Q2 25 | $376.4M | $213.7M | ||
| Q1 25 | $375.6M | $274.2M | ||
| Q4 24 | $351.8M | $259.7M | ||
| Q3 24 | $381.0M | $301.4M | ||
| Q2 24 | $376.0M | $348.3M |
总资产FRSTRGNX
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.0B | $453.0M | ||
| Q3 25 | $4.0B | $525.2M | ||
| Q2 25 | $3.9B | $581.0M | ||
| Q1 25 | $3.7B | $490.9M | ||
| Q4 24 | $3.7B | $466.0M | ||
| Q3 24 | $4.0B | $519.1M | ||
| Q2 24 | $4.0B | $569.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FRSTRGNX
| Q1 26 | — | — | ||
| Q4 25 | $10.8M | $-52.3M | ||
| Q3 25 | $-11.4M | $-56.0M | ||
| Q2 25 | $-41.0M | $-49.3M | ||
| Q1 25 | $34.4M | $33.6M | ||
| Q4 24 | $19.5M | $-31.6M | ||
| Q3 24 | $6.1M | $-40.5M | ||
| Q2 24 | $52.3M | $-45.5M |
自由现金流FRSTRGNX
| Q1 26 | — | — | ||
| Q4 25 | $9.0M | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | $18.3M | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M |
自由现金流率FRSTRGNX
| Q1 26 | — | — | ||
| Q4 25 | 11.2% | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | 47.3% | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% |
资本支出强度FRSTRGNX
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 3.1% | 5.1% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 2.1% |
现金转化率FRSTRGNX
| Q1 26 | — | — | ||
| Q4 25 | 0.36× | — | ||
| Q3 25 | -1.67× | — | ||
| Q2 25 | -16.82× | — | ||
| Q1 25 | 1.52× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.93× | — | ||
| Q2 24 | 15.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FRST
| Net Interest Income | $32.1M | 70% |
| Noninterest Income | $13.6M | 30% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
